13F Holdings
中文EN

OLMA Olema Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1750284 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-69.8%
ROA-59.5%
ROIC (approx.)-67.3%
Asset turnover—

Leverage & solvency

Liabilities / assets16.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$157.70M$124.52M$86.14M$82.27M$51.10M
SG&A expense$21.00M$17.74M$18.82M$24.71M$20.39M
Operating income-$178.70M-$142.26M-$104.96M-$106.99M-$71.49M
Pretax income-$162.45M-$129.47M———
Income tax$3,000$2,000$2,000$1,000—
Net income-$162.45M-$129.47M-$96.66M-$104.79M-$71.10M
EBITDA-$178.21M-$141.87M-$104.58M-$106.63M-$71.33M
EPS (basic)-1.87-2.20-2.14-2.62-1.80
EPS (diluted)-1.87-2.20-2.14-2.62-1.80
Weighted avg. shares (diluted)87.01M58.74M45.25M40.00M39.52M
Balance sheet
Cash & equivalents$48.30M$139.48M$68.54M$23.70M$13.81M
Short-term investments$457.14M$294.61M$193.27M$180.72M$273.44M
Current assets$515.45M$438.47M$266.51M$208.90M$290.69M
PP&E, net$274,000$746,000$968,000$1.48M$1.47M
Total assets$533.43M$450.98M$276.94M$215.65M$295.94M
Current liabilities$51.80M$41.76M$21.62M$16.55M$9.02M
Total liabilities$54.87M$42.02M$23.05M$18.10M$11.38M
Shareholders' equity$478.56M$408.96M$253.90M$197.55M$284.57M
Shares outstanding81.38M74.31M54.99M40.29M39.80M
Cash flow statement
Operating cash flow-$146.72M-$104.35M-$83.73M-$82.06M-$50.69M
Capital expenditure—$159,000—$363,000$1.57M
Free cash flow—-$104.51M—-$82.43M-$52.27M
Investing cash flow-$155.76M-$93.53M-$4.85M$91.48M-$275.44M
Financing cash flow$211.30M$268.82M$133.41M$476,000$1.39M
Depreciation & amortization$490,000$393,000$377,000$357,000$163,000
Stock-based compensation$17.59M$22.58M$17.26M$18.83M$15.91M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.